Literature DB >> 31846841

Upregulation of DPY30 promotes cell proliferation and predicts a poor prognosis in cholangiocarcinoma.

Zai-Fa Hong1, Wen-Qing Zhang2, Shuang-Jia Wang3, Si-Yang Li4, Jin Shang4, Fan Liu5, Dong-Yan Shen6.   

Abstract

OBJECTIVES: Modification of lysine 4 on histone H3 methylation by SET1 and MLL family methyltransferase complexes is tightly linked to cancer progression. DPY30 is an important subunit of SET1 and MLL complexes, however, its expression and roles in cancer progression was little known, especially in cholangiocarcinoma (CCA).
MATERIALS AND METHODS: The Q-PCR and IHC were performed to detect the levels of DPY30 mRNA and protein in CCA tissues. Effect of DPY30 knockdown on the proliferation of CCA cells was detected by MTS and colony formation, and cell cycle distribution was analyzed by flow cytometer. The glucose uptake, lactate release and ATP production assays were performed to detect the glycolysis of CCA cells.
RESULTS: The level of DPY30 mRNA and protein in CCA tissues were all significantly higher than that of pericancer tissues, and its upregulation was closely associated with pathological differentiation, tumor size, and TNM stage. In addition, Kaplan-Meier analysis of overall survival revealed that DPY30 upregulation was significantly associated with poor survival, and univariate and multivariate analysis indicated that it was an independently prognosis factor in CCA patients. Moreover, DPY30 knockdown inhibited in-vitro growth and induced cell cycle arrest at G2/M and decreased glycolysis in CCA cells.
CONCLUSIONS: DPY30 upregulation may promote the development of CCA and was associated with the aggressive malignant behavior and poor survival outcome of CCA patients. DPY30 might serve as a potential novel target for treatment of CCA patients.
Copyright © 2019 The Author(s). Published by Elsevier Masson SAS.. All rights reserved.

Entities:  

Keywords:  Cell cycle; Cholangiocarcinoma; DPY30; Glycolysis

Year:  2019        PMID: 31846841     DOI: 10.1016/j.biopha.2019.109766

Source DB:  PubMed          Journal:  Biomed Pharmacother        ISSN: 0753-3322            Impact factor:   6.529


  2 in total

1.  DPY30 acts as an ASH2L-specific stabilizer to stimulate the enzyme activity of MLL family methyltransferases on different substrates.

Authors:  Lijie Zhao; Naizhe Huang; Jun Mencius; Yanjing Li; Ying Xu; Yongxin Zheng; Wei He; Na Li; Jun Zheng; Min Zhuang; Shu Quan; Yong Chen
Journal:  iScience       Date:  2022-08-16

2.  The DPY30-H3K4me3 Axis-Mediated PD-L1 Expression in Melanoma.

Authors:  Zhichun Zhang; Yixuan Han; Qiuyue Sun; Yipeng Wang; Lichao Sun
Journal:  J Inflamm Res       Date:  2022-09-26
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.